Topical β-Blockers and Mortality

Purpose To study the associations between long-term and short-term use of topical β-blockers and mortality. Design Prospective population-based cohort study. Participants To examine long-term effects, 3842 participants aged 55 years and older were recruited. To examine short-term effects, 484 incident β-blocker users and 4700 age-matched controls were recruited. All participants were recruited as part of the Rotterdam Study. Methods To examine long-term effects, associations between topical β-blocker use before and at baseline, between 1990 and 1997, and mortality between 1997 and 2005 were studied. Data were analyzed using Cox regression, and hazard ratios were adjusted for age, gender, smoking, systemic hypertension, diabetes mellitus, and angina pectoris. Short-term effects were defined as death within 3 months after the first prescription of a topical β-blocker. Mortality was compared between incident β-blocker users, that is, participants who started using a topical β-blocker between the onset of the Rotterdam Study in 1990 and October 1, 2004, and age-matched controls. Short-term effects were examined using a chi-square test. Confounding by smoking was analyzed by stratification. Main Outcome Measures For long-term effects, hazard ratios of topical β-blocker use for all-cause mortality and cardiovascular mortality; for short-term effects, chi-square statistics between mortality of incident topical β-blocker users and age-matched controls. Results With regard to long-term effects, mean age at baseline was 72 years (standard deviation, 7 years). Topical β-blockers were used by 228 participants. Seven hundred nine participants died during the follow-up (18%); 135 (3.5%) died of a cardiovascular cause. The hazard ratio of topical β-blocker use was 0.94 (95% confidence interval [CI], 0.71–1.25; P = 0.69) for all-cause mortality and 1.02 (95% CI, 0.56–1.86; P = 0.95) for cardiovascular mortality. With regard to short-term effects, 4 (0.8%) of the 484 incident topical β-blocker users died within 3 months after their first prescription; 65 (1.4%; P = 0.31) of the 4700 aged-matched controls died within a similar period. Conclusions Use of topical β-blockers seems not to be associated with excess mortality. Financial Disclosure(s) The authors have no proprietary or commercial interest in any materials discussed in this article.